JIUN-KAE JACK LEE to Patient Selection
This is a "connection" page, showing publications JIUN-KAE JACK LEE has written about Patient Selection.
Connection Strength
0.203
-
Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement. Clin Cancer Res. 2017 Mar 15; 23(6):1414-1421.
Score: 0.083
-
RE: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. J Natl Cancer Inst. 2013 Jun 05; 105(11):833.
Score: 0.063
-
Design considerations for efficient prostate cancer chemoprevention trials. Urology. 2001 Apr; 57(4 Suppl 1):205-12.
Score: 0.027
-
Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer. 2006 Aug 01; 107(3):563-9.
Score: 0.010
-
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst. 2006 Apr 05; 98(7):441-50.
Score: 0.010
-
Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999 May 05; 91(9):763-71.
Score: 0.006
-
Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center. J Clin Oncol. 1996 Jan; 14(1):287-95.
Score: 0.005